Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCCAP.L Regulatory News (CCAP)

  • There is currently no data for CCAP

Interim Management Statement

11 Jul 2012 07:00

RNS Number : 3769H
Charlemagne Capital Limited
11 July 2012
Β 

ο»Ώ

11 July 2012

Β 

Β 

Interim Management Statement for the Six Months Ended 30 June 2012

Β 

Β 

Charlemagne Capital Limited ("Charlemagne" or the "Group") sets out below the key revenue items and Assets under Management ("AuM") for the first six months of its current financial year.It is expected that the interim financial results will be announced on 18 September 2012.

Β 

Key highlights and Group AuM

Β 

Β§ As at 30 June 2012, Group AuM were US$2.3 billion, down by 2.2% since 1 January 2012;

Β 

Β§ Net management fees of US$9.7 million, down 7.6% on the previous six months; and

Β 

Β·; The Group remains well-capitalised with a strong and liquid balance sheet.

Β 

The table below sets out the Group's AuM as at 30 June 2012 and the movements experienced in each product range in the period since 1 January 2012.

Β 

Β 

Β 

01-Jan-12

Net Subscriptions

Net Performance

30-Jun-12

Movement In

AuM (US$m)

(US$m)

(%)

(US$m)

(%)

AuM (US$m)

Period (%)

Magna

260

39

15.0

7

2.5

306

17.7

OCCO

444

50

11.3

18

3.8

512

15.3

Institutional

1,452

(229)

(15.8)

79

5.9

1,302

(10.3)

Specialist

172

(10)

(5.8)

(5)

(3.0)

157

(8.7)

Total

2,328

(150)

(6.4)

99

4.4

2,277

(2.2)

Β 

Notes:

Closing AuM is stated as including all subscription and redemption orders received for the relevant funds as at the close of the period but not processed until the first dealing date of the following period.

Β 

Unaudited revenue numbers for the six months ended 30 June 2012

Β 

Net management fees receivable were US$9.7 million compared with US$10.5 million for the previous six months and US$12.1 million for the comparable period of 2011, reflecting the lower average AuM offset in part by an increase in net margin in the first half of 2012.

Β 

Crystallised performance fees were US$0.9 million compared with US$0.1 million for the comparative period in 2011.

Β 

Accruing performance fees1 for 2012 which have not crystallised were US$3.5 million compared with US$1.5 million as at the same date in 2011.

Β 

Β 

Β 

Β 

____________________________________________________________________________

1Performance fees accrue throughout the reporting period in the accounts of each relevant fund. It is the group's accounting policy only to recognise such revenues as they crystallise at the year-end date of the fund or, in certain cases, on redemption. Levels of accrued performance fees at any particular time should not be seen as necessarily indicative of the eventual crystallised figures, especially in periods of above average market volatility.

Β 

Summary

Β 

After a strong opening two months of the year, emerging markets softened over the remainder of the first half, as macroeconomic data from most major economies of the world came below expectations. This in turn increases the likelihood that earnings forecasts, both in developed and emerging economies will be revised downwards, although valuations in the emerging markets already appear to have discounted this outcome. Oil importing Turkey, whose market rose 28% over the six months in US$, was one of the best performers, while amongst the larger markets Brazil lagged, with a decline of 8%.

Β 

Over the period, the relative performance of Charlemagne's equity strategies was strong, with six of the eight Magna sub-funds in the top half of their FactSet Morningstar peer group comparisons and none in the bottom quartile.

Β 

There have been positive net inflows into the Magna funds over the first half of the year particularly into the Latin American and GEMs Dividend strategies. Institutional mandates experienced outflows mainly in the first quarter which was partially offset in the second quarter with the acquisition of a new US$130 million institutional Latin American mandate. The OCCO Eastern European Fund reopened during the period and the US$120 million new capacity has been fully allocated with US$70 million still to be invested in the third quarter. The fund has therefore been closed once again to new investors.

Β 

The trading environment remains challenging, with markets volatile, investor confidence fragile and fund flows subdued. The Group has negotiated these conditions well; achieving the key objective of making money for our investors, but overall reduced asset values has had a direct impact on group revenues. We have continued to improve operational efficiency and to take action on costs, where such measures are not to the detriment of delivering investment performance for clients, but market values will need to rise in order for the group to see meaningful levels of profitability from recurring fee sources.

Β 

Β 

Β 

Enquiries:

Β 

Charlemagne Capital

Β 

Jayne Sutcliffe, Chief Executive

Tel. 020 7518 2100

Lloyd Jones, Finance Director

Tel. 01624 640200

Β 

Β 

Singer Capital Markets Ltd

+44 203 205 7500

Jonny Franklin-Adams

Β 

Β 

Β 

Smithfield Consultants

Tel. 020 7360 4900

John Kiely

Ged Brumby

Β 

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSKMGMNNGZGZZM
Date   Source Headline
15th Mar 20167:01 amRNSDividend Declaration
15th Mar 20167:00 amRNSFinal Results
17th Feb 20163:07 pmRNSTR1 - Notification of Major Interest in Shares
19th Jan 20167:00 amRNSTrading Statement
27th Nov 201511:28 amRNSForm 8.3 - Al Noor Hospitals Group PLC
26th Nov 201510:42 amRNSForm 8.3 - Al Noor Hospitals Group PLC
25th Nov 201510:48 amRNSForm 8.3 - Al Noor Hospitals Group PLC
23rd Nov 201511:56 amRNSForm 8.3 - Al Noor Hospitals Group PLC
19th Nov 201510:56 amRNSForm 8.3 -NMC Health PLC
18th Nov 201511:29 amRNSForm 8.3 - Al Noor Hospitals Group PLC
17th Nov 201510:25 amRNSForm 8.3 - NMC Health PLC
17th Nov 20159:42 amRNSForm 8.3 - Al Noor Hospitals Group PLC
17th Nov 20159:35 amRNSForm 8.3 - NMC Health Plc
9th Nov 201511:38 amRNSForm 8.3 - Al Noor Hospitals
4th Nov 20154:32 pmRNSForm 8.3 - NMC Health Plc
28th Oct 201511:34 amRNSForm 8.3 - Al Noor Hospitals
28th Oct 201511:30 amRNSForm 8.3 - NMC Health PLC
16th Oct 201511:27 amRNSHolding(s) in Company
9th Oct 20157:00 amRNSQ3 2015 AUM Update
22nd Sep 20157:01 amRNSDividend Declaration
22nd Sep 20157:00 amRNSHalf Yearly Report
15th Jul 20157:00 amRNSInterim Management Statement
19th Jun 20156:00 pmRNSHolding(s) in Company
19th Jun 201512:17 pmRNSResult of AGM
15th May 20153:05 pmRNSAnnual Report and Notice of AGM
29th Apr 20156:06 pmRNSHolding(s) in Company
10th Apr 20157:00 amRNSQ1 2015 AUM Update
30th Mar 20159:00 amRNSQuadruple Lipper Award Win for Charlemagne Capital
17th Mar 20157:05 amRNSDividend Declaration
17th Mar 20157:00 amRNSFinal Results
13th Jan 20157:00 amRNSTrading Statement
23rd Dec 20144:28 pmRNSDirector/PDMR Shareholding
10th Oct 20147:00 amRNSQ3 2014 AUM Update
18th Sep 201410:38 amRNSDirector/PDMR Shareholding
17th Sep 201411:46 amRNSDirector/PDMR Shareholding
16th Sep 20147:30 amRNSDividend Declaration
16th Sep 20147:00 amRNSHalf Yearly Report
15th Jul 20147:00 amRNSInterim Management Statement
20th Jun 20144:02 pmRNSResult of AGM
19th May 20149:20 amRNSMAGNA MENA FUND REACHES 3 YEAR ANNIVERSARY
14th May 20142:38 pmRNSNotice of AGM
14th May 20147:00 amRNSDirector/PDMR Shareholding
9th May 20148:16 amRNSTriple Lipper Award Win for Charlemagne Capital
28th Apr 20143:27 pmRNSChange to Significant Shareholding
25th Apr 201412:49 pmRNSHolding(s) in Company
25th Apr 201410:30 amRNSHolding(s) in Company
8th Apr 20147:00 amRNSQ1 2014 AUM Update
18th Mar 20147:05 amRNSDividend Declaration
18th Mar 20147:00 amRNSFinal Results
14th Jan 20144:12 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.